Delving into the Latest Updates on AZD-2516 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

AZD 2516, AZD2516

Target

mGluR5

Action

antagonists

Mechanism

mGluR5 antagonists(Metabotropic glutamate receptor 5 antagonists)

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication-

Inactive Indication

Neuralgia

Originator Organization

AstraZeneca PLC

Active Organization-

Inactive Organization

AstraZeneca PLC

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

AZD2516 is being developed for the oral treatment of chronic neuropathic pain. This study is split in to two parts. Part A will measure the effect of food and a new formulation of the drug in the blood and see how well it is tolerated. Part B will commence after the completion of Part A and will investigate the safety and tolerability of daily dosing with AZD2516.

Start Date01 Jun 2010

Sponsor / Collaborator

AstraZeneca PLC

[+1]

NL-OMON34821

/ SuspendedPhase 2

A double-blind, randomized, placebo-controlled, two-centre, phase IIa pharmacodynamic cross-over study to assess the effect of AZD2516 on the total number of reflux episodes in healthy male volunteers - PoP study AZD2516

Start Date01 Jun 2010

Sponsor / Collaborator-

NCT01154634

/ CompletedPhase 2

A Double-blind, Randomized, Placebo-controlled, Two-centre, Phase IIa Pharmacodynamic Cross-over Study to Assess the Effect of AZD2516 on the Total Number of Reflux Episodes in Healthy Male Volunteers

The purpose of this study is to investigate the pharmacodynamic effect of AZD2516 in healthy male subjects.

Start Date01 May 2010

Sponsor / Collaborator

AstraZeneca PLC

100 Clinical Results associated with AZD-2516

Login to view more data

100 Translational Medicine associated with AZD-2516

Login to view more data

100 Patents (Medical) associated with AZD-2516

Login to view more data

100 Deals associated with AZD-2516

Login to view more data